These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35960075)

  • 1. Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: A pilot study.
    Li X; Guo X; Li J; Yuan L; Wang H
    Medicine (Baltimore); 2022 Aug; 101(32):e30000. PubMed ID: 35960075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
    Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X
    Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
    Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
    Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
    Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
    Tahir E; Azar M; Shihada S; Seiffert K; Goy Y; Beitzen-Heineke A; Molwitz I; Muellerleile K; Stehning C; Schön G; Adam G; Petersen C; Müller V; Lund GK
    Eur Radiol; 2022 Mar; 32(3):1853-1865. PubMed ID: 34536111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
    Mo Z; Deng Y; Bao Y; Liu J; Jiang Y
    Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients.
    Nisticò C; Bria E; Cuppone F; Carpino A; Ferretti G; Vitelli G; Sperduti I; Calabretta F; Toglia G; Tomao S; Cognetti F; Terzoli E
    Anticancer Drugs; 2007 Feb; 18(2):227-32. PubMed ID: 17159609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
    Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
    [No Abstract]   [Full Text] [Related]  

  • 11. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
    Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
    Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity.
    Maini CL; Sciuto R; Ferraironi A; Vici P; Tofani A; Festa A; Conti F; Lopez M
    J Nucl Cardiol; 1997; 4(6):502-8. PubMed ID: 9456190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
    Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
    Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
    Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
    Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
    Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
    Wang P; Zhang S; Zhang XB; Li WJ; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients].
    Huang WB; Yao GY; Liu MF; Chen RT; Chen LJ; Dong JY; Gu F; Guo ZZ; Ye CS
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1047-50. PubMed ID: 21690066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt/GSK-3β signaling pathway.
    Abbas NAT; Kabil SL
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Nov; 390(11):1145-1153. PubMed ID: 28780599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography.
    Cottin Y; Touzery C; Dalloz F; Coudert B; Toubeau M; Riedinger A; Louis P; Wolf JE; Brunotte F
    Clin Cardiol; 1998 Sep; 21(9):665-70. PubMed ID: 9755384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.